Strategy and planning for chemopreventive drug development: Clinical development plans
- 1 January 1994
- journal article
- guideline
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 56 (S20), 55-62
- https://doi.org/10.1002/jcb.240560906
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- NSAIDs: time to re-evaluate gut toxicityThe Lancet, 1994
- Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Tamoxifen: Trials, Tribulations, and Trade-offsJNCI Journal of the National Cancer Institute, 1994
- NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitroProstaglandins, 1994
- Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 ratsCarcinogenesis: Integrative Cancer Research, 1993
- Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicamCarcinogenesis: Integrative Cancer Research, 1993
- A protective effect of sulindac against chemically‐induced primary colonic tumours in miceThe Journal of Pathology, 1988
- Antitumor effects of inhibitors of arachidonic acid cascade on experimentally induced intestinal tumorsDiseases of the Colon & Rectum, 1987
- The suppressive effect of piroxicam on autochthonous intestinal tumors in the ratCancer Letters, 1983
- Kinetics of α-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylaseClinical Pharmacology & Therapeutics, 1981